MyMedR

Displaying all 4 publications

Abstract:

Sort:

Fulltext A rapid supercritical water approach for one-pot synthesis of a branched BiVO4/RGO composite as a Li-ion battery anode

Rangappa D, Manickavasakam K, Muniyappa M, Bekal C, Shenoy B S, Misnon II, et al.

RSC Adv, 2024 Feb 29;14(11):7699-7709.
PMID: 38444968 DOI: 10.1039/d3ra07731d

The application of novel one-dimensional (1D) architectures in the field of energy storage has fascinated researchers for a long time. The fast-paced technological advancements require reliable rapid synthesis techniques for the development of various Multi-metal oxide (MMO) nanostructures. For the first time, we report the synthesis of a single-phase hierarchical one-dimensional (1D) branched BiVO4-Reduced Graphene Oxide (BVONB/RGO) nanocomposite with different weight percent variations of RGO starting from 6, 12, 24, and 26 wt% using the supercritical water method (SCW). The affirmation of the sample characteristics is done through various nano-characterization tools that help in establishing the monoclinic crystal structure, and nano branch morphology along with its physical, and thermal characteristics. Further, the electrochemical behavior evaluations of the fabricated coin cells provide insights into the well-known superior initial cycle capacity of around 810 mA h g-1, showing the superior ability of BVONB structures in storing lithium-ions (Li-ions). Meanwhile, an improved cyclic performance of the pure BVONB/RGO with 260 mA h g-1 is evident after 50 cycles. Finally, the reported rapid single-pot SCW approach has delivered promising results in establishing a material process technique for multimetal oxides and their RGO nanocomposites successfully.
Nasal airflow comparison in neonates, infant and adult nasal cavities using computational fluid dynamics

Corda JV, Shenoy BS, Ahmad KA, Lewis L, K P, Khader SMA, et al.

Comput Methods Programs Biomed, 2022 Feb;214:106538.
PMID: 34848078 DOI: 10.1016/j.cmpb.2021.106538

BACKGROUND AND OBJECTIVE: Neonates are preferential nasal breathers up to 3 months of age. The nasal anatomy in neonates and infants is at developing stages whereas the adult nasal cavities are fully grown which implies that the study of airflow dynamics in the neonates and infants are significant. In the present study, the nasal airways of the neonate, infant and adult are anatomically compared and their airflow patterns are investigated.
METHODS: Computational Fluid Dynamics (CFD) approach is used to simulate the airflow in a neonate, an infant and an adult in sedentary breathing conditions. The healthy CT scans are segmented using MIMICS 21.0 (Materialise, Ann arbor, MI). The patient-specific 3D airway models are analyzed for low Reynolds number flow using ANSYS FLUENT 2020 R2. The applicability of the Grid Convergence Index (GCI) for polyhedral mesh adopted in this work is also verified.
RESULTS: This study shows that the inferior meatus of neonates accounted for only 15% of the total airflow. This was in contrast to the infants and adults who experienced 49 and 31% of airflow at the inferior meatus region. Superior meatus experienced 25% of total flow which is more than normal for the neonate. The highest velocity of 1.8, 2.6 and 3.7 m/s was observed at the nasal valve region for neonates, infants and adults, respectively. The anterior portion of the nasal cavity experienced maximum wall shear stress with average values of 0.48, 0.25 and 0.58 Pa for the neonates, infants and adults.
CONCLUSIONS: The neonates have an underdeveloped nasal cavity which significantly affects their airway distribution. The absence of inferior meatus in the neonates has limited the flow through the inferior regions and resulted in uneven flow distribution.
Comparison of microparticle transport and deposition in nasal cavity of three different age groups

Valerian Corda J, Shenoy BS, Ahmad KA, Lewis L, K P, Rao A, et al.

Inhal Toxicol, 2024 Jan;36(1):44-56.
PMID: 38343121 DOI: 10.1080/08958378.2024.2312801

Objective: The nasal cavity effectively captures the particles present in inhaled air, thereby preventing harmful and toxic pollutants from reaching the lungs. This filtering ability of the nasal cavity can be effectively utilized for targeted nasal drug delivery applications. This study aims to understand the particle deposition patterns in three age groups: neonate, infant, and adult.Materials and methods: The CT scans are built using MIMICS 21.0, followed by CATIA V6 to generate a patient-specific airway model. Fluid flow is simulated using ANSYS FLUENT 2021 R2. Spherical monodisperse microparticles ranging from 2 to 60 µm and a density of 1100 kg/m3 are simulated at steady-state and sedentary inspiration conditions.Results: The highest nasal valve depositions for the neonate are 25% for 20 µm, for infants, 10% for 50 µm, 15% for adults, and 15% for 15 µm. At mid nasal region, deposition of 15% for 20 µm is observed for infant and 8% for neonate and adult nasal cavities at a particle size of 10 and 20 µm, respectively. The highest particle deposition at the olfactory region is about 2.7% for the adult nasal cavity for 20 µm, and it is <1% for neonate and infant nasal cavities.Discussion and conclusions: The study of preferred nasal depositions during natural sedentary breathing conditions is utilized to determine the size that allows medication particles to be targeted to specific nose regions.
Fulltext Continuous positive airway pressure and adverse cardiovascular events in obstructive sleep apnea: are participants of randomized trials representative of sleep clinic patients?

Reynor A, McArdle N, Shenoy B, Dhaliwal SS, Rea SC, Walsh J, et al.

Sleep, 2022 Apr 11;45(4).
PMID: 34739082 DOI: 10.1093/sleep/zsab264

STUDY OBJECTIVES: Randomized controlled trials (RCTs) have shown no reduction in adverse cardiovascular (CV) events in patients randomized to continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA). This study examined whether randomized study populations were representative of OSA patients attending a sleep clinic.
METHODS: Sleep clinic patients were 3,965 consecutive adults diagnosed with OSA by in-laboratory polysomnography from 2006 to 2010 at a tertiary hospital sleep clinic. Characteristics of these patients were compared with participants of five recent RCTs examining the effect of CPAP on adverse CV events in OSA. The percentage of patients with severe (apnea-hypopnea index, [AHI] ≥ 30 events/h) or any OSA (AHI ≥ 5 events/h) who met the eligibility criteria of each RCT was determined, and those criteria that excluded the most patients identified.
RESULTS: Compared to RCT participants, sleep clinic OSA patients were younger, sleepier, more likely to be female and less likely to have established CV disease. The percentage of patients with severe or any OSA who met the RCT eligibility criteria ranged from 1.2% to 20.9% and 0.8% to 21.9%, respectively. The eligibility criteria that excluded most patients were preexisting CV disease, symptoms of excessive sleepiness, nocturnal hypoxemia and co-morbidities.
CONCLUSIONS: A minority of sleep clinic patients diagnosed with OSA meet the eligibility criteria of RCTs of CPAP on adverse CV events in OSA. OSA populations in these RCTs differ considerably from typical sleep clinic OSA patients. This suggests that the findings of such OSA treatment-related RCTs are not generalizable to sleep clinic OSA patients.Randomized Intervention with Continuous Positive Airway Pressure in CAD and OSA (RICCADSA) trial, https://clinicaltrials.gov/ct2/show/NCT00519597, ClinicalTrials.gov number, NCT00519597.Usefulness of Nasal Continuous Positive Airway Pressure (CPAP) Treatment in Patients with a First Ever Stroke and Sleep Apnea Syndrome, https://clinicaltrials.gov/ct2/show/NCT00202501, ClinicalTrials.gov number, NCT00202501.Effect of Continuous Positive Airway Pressure (CPAP) on Hypertension and Cardiovascular Morbidity-Mortality in Patients with Sleep Apnea and no Daytime Sleepiness, https://clinicaltrials.gov/ct2/show/NCT00127348, ClinicalTrials.gov number, NCT00127348.Continuous Positive Airway Pressure (CPAP) in Patients with Acute Coronary Syndrome and Obstructive Sleep Apnea (OSA) (ISAACC), https://clinicaltrials.gov/ct2/show/NCT01335087, ClinicalTrials.gov number, NCT01335087.